Patents by Inventor Jörg Schneider

Jörg Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050175627
    Abstract: The invention relates to a recombinant polypeptide comprising amino acid sequence derived from at least one of an HIV gag gene product; an HIV pol gene product; or an HIV nef gene product, said sequence being mutated with respect to the natural sequence of said gene product, and said sequence maintaining each of the naturally occurring CD8+ T cell epitopes of said gene product as defined in p17 and p24 (gag), amino acids 1-440 of RT (pol) and nef shown in Example 8. Furthermore the invention relates to nucleic acids encoding same, and viral vectors encoding same, and to their use in medicine and in immunisation and vaccination.
    Type: Application
    Filed: December 9, 2004
    Publication date: August 11, 2005
    Applicant: Oxxon Therapeutics Ltd.
    Inventor: Joerg Schneider
  • Publication number: 20040249149
    Abstract: A process is described for preparing alkoxycarbonylaminotriazines by reacting di- or triaminotriazines with dimethyl carbonate in the presence of an alcohol and of an alkali metal or alkaline earth metal methoxide base.
    Type: Application
    Filed: March 31, 2004
    Publication date: December 9, 2004
    Inventors: Joerg Schneider, Gunter Scherr, Hans Schupp, Andreas Eichfelder, Alain Robert, Martin Reif
  • Publication number: 20040018177
    Abstract: There is provided a method of inducing a CD4+ T-cell response against a target antigen, by administering a composition a source of one or more CD4+ epitopes is a non-replicating or replication impaired recombinant poxvirus vector.
    Type: Application
    Filed: July 15, 2003
    Publication date: January 29, 2004
    Inventors: Adrian V.S. Hill, Helen McShane, Sarah Gilbert, Joerg Schneider
  • Patent number: 6663871
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: December 16, 2003
    Assignee: Oxxon Pharmaccines Ltd.
    Inventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
  • Publication number: 20030138454
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. There is also provided a method of inducing a CD4+ T-cell response against a target antigen, by administering a composition comprising a source of one or more CD4+ T cell epitopes of the target antigen wherein the source of CD4+ epitopes is a non-replicating or replication impaired recombinant poxvirus vector. A method of inducing a combined CD4+ and CD8+ T cell response against a target antigen is also described herein.
    Type: Application
    Filed: February 19, 2002
    Publication date: July 24, 2003
    Applicant: Oxxon Pharmaccines, Ltd.
    Inventors: Adrian V. S. Hill, Helen McShane, Sarah C. Gilbert, William Reece, Joerg Schneider